Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

Vertex Pharmaceuticals and Orna Therapeutics announce a $4 billion collaboration to develop in vivo gene editing therapies ...

Finbold has selected three interesting pharmaceutical stocks that could see significant moves to the upside in 2025.

Vertex Pharmaceuticals Inc. closed $111.56 below its 52-week high ($519.88), which the company achieved on November 8th.

Sana Biotechnology, Inc. shares surge as a breakthrough in diabetes therapy sparks investor interest. Click for my updated ...

My 2024 picks outperformed the S&P 500, mainly due to Tesla, but small biotech firms lagged significantly. Learn more about ...

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

So VeriSign's still-low invested capital supports its high current ROIC. On an adjusted basis, the company's ROIC was 4.4% for 2023, with a five-year average of 3.9%, according to the data provided by ...

As the healthcare real estate market flourishes, fueled by demographic transformations and cutting-edge advancements in ...

As the demand for targeted demographics and accurate forecasts continues to rise, the popularity of data analytics is soaring ...

US stocks sold off sharply on Tuesday as bond yields hit a nine-month high on the back of stronger-than-expected economic ...

With Nvidia and Continental onboard, Aurora is gearing up to transform autonomous trucking at an unprecedented scale.